Immunohistochemical staining of Glypican-3  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

Glypican-3 [YP-7] Antibody (cGMP).

$ 135.00$ 575.00
Please Select Product Options Below To View The Catalog Number.

SKU: QIVD280
Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Mouse IgG1, kappa

Product NumberDescriptionPrice
QIVD280-0.1ml Size: 0.1 ml, Format: Concentrate $ 135.00
QIVD280-0.5ml Size: 0.5 ml, Format: Concentrate $ 415.00
QIVD280-1ml Size: 1 ml, Format: Concentrate $ 575.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:

Purity:

Bioactivity (test results eg. IU/ml):


SKU: QIVD280-0.1ml
Glypican-3 General Information
Alternate Names
Molecular Weight
65.6 kDa
Chromosomal Location
q26.2 [chr: X] [chr_start: 133535745] [chr_end: 133985895] [strand: -1]
Curated Database and Bioinformatic Data
Gene SymbolGPC3
Entrez Gene ID2719
RefSeq Protein Accession(s)NP_001158089; NP_004475; NP_001158091
RefSeq mRNA Accession(s)XM_017029413; NM_001164618; NM_001164617; NM_004484; NM_001164619
RefSeq Genomic Accession(s)NG_009286; NC_000023
UniProt ID(s)P51654
PharmGKB ID(s)PA28832
KEGG Gene ID(s)hsa:2719
Associated Diseases (KEGG IDs)Simpson-Golabi-Behmel syndrome 1 (SGBS1) [MIM:312870]: A condition characterized by pre- and postnatal overgrowth (gigantism), facial dysmorphism and a variety of inconstant visceral and skeletal malformations. Characteristic dysmorphic features include macrocephaly with coarse, distinctive facies with a large protruding jaw, broad nasal bridge and cleft palate. Cardiac defects are frequent. {ECO:0000269|PubMed:10814714}. The disease is caused by mutations affecting the gene represented in this entry.
General Description of Glypican-3 .
Glypican-3 (GPC3) is a glycosylphospatidyl inositol-anchored membrane protein, which may also be found in a secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilms’ tumor. In patients with HCC, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and the serum of healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of hepatic adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up regulated in certain histologic subtypes, specifically yolk sac tumors and choriocarcinoma. A high level of GPC3 expression is also found in some types of embryonal tumors, such as Wilms’ tumor and hepatoblastoma, with a low or undetectable expression in normal adjacent tissue. In patients with thyroid cancer, expression of GPC3 is dramatically enhanced in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. Expression of GPC3 in follicular carcinoma is significantly higher than that offollicular adenoma.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:50-1:100
Pretreatment EDTA Buffer pH 8.0
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Monoclonal
Anti-Glypican-3 Antibody Clone: YP-7
Host and Isotype: Mouse IgG1, kappa
Recommended Positive Control Sample: Thyroid carcinoma, Hepatocellular carcinoma
Cellular Localization of Antibody YP-7 Staining: Cytoplasmic
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: Recombinant full-length human GPC3 protein
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

Glypican-3 Information for Pathologists

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “Glypican-3 [YP-7] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title

Materials

Methods

Notes


  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Phone: 1-855-344-1400 | enquire@enquirebio.com | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

Glypican-3 [YP-7] Antibody (cGMP).